Grace Science receives U.S. FDA orphan drug designation for GS-100, an AAV9 Gene Therapy for NGLY1 deficiency


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
Latest FDA drug approval update

Grace Science, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GS-100, an investigational AAV9 gene replacement therapy for the treatment of NGLY1 deficiency.

The FDA grants orphan drug designation to investigational medicines and biologics intended for the safe and effective treatment, diagnosis, or prevention of rare disease or conditions affecting fewer than 200,000 people in the United States.

Orphan drug designation provides certain benefits and incentives to Grace Science for developing a gene therapy for NGLY1 deficiency, including seven years of U.S. marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain clinical research costs, eligibility for orphan drug grants, and a waiver of the Prescription Drug User Fee Act (PDUFA) filing fees.

NGLY1 deficiency is an ultra-rare genetic disease caused by loss of function mutations in the NGLY1 gene. The disease primarily affects children and manifests as a complex neurological syndrome that includes global developmental delay, cognitive impairment, movement disorders, abnormal tear production (alacrima), as well as other neurological symptoms. There is currently no approved therapy for NGLY1 deficiency.

Matt Wilsey, founder and CEO of Grace Science stated: “We are pleased the FDA has granted orphan drug designation to our gene therapy program for NGLY1 deficiency. This action highlights the significant need that exists for the development of safe and effective treatments for children suffering from this condition, including my own daughter, Grace. Our recent interactions with the FDA have been highly productive and we are making rapid progress on our plans to file an investigational new drug application (IND) in the third quarter of Q3 2022, which would allow us to initiate our first clinical trial by the end of next year.”

Grace Science recently closed its Series A financing, which will fund the advancement of GS-100 into a first-in-human clinical trial for NGLY1 deficiency. The viral vector development and clinical manufacturing services for GS-100 will be provided by Thermo Fisher Scientific at its site in Alachua, FL.

Tags : #GraceScience #USFDA #FDA #AAV9GeneTherapy #GS100

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Reforming global financial architecture is critical for gender equality and right to healthJuly 14, 2025
Francesco Arezzo takes office as president of Rotary InternationalJuly 14, 2025
CBM India Highlights Inclusive Eye Health at VISION 2020: The Right to Sight – INDIA 19th Annual ConferenceJuly 14, 2025
Crompton Introduces Ameo Fresh Nutri Blender, Reinforcing Its Promise of ‘Healthy Choices Made Easy’July 14, 2025
NMC Notifies Medical Institutions (Qualifications of Faculty) Regulations, 2025 to Expand Medical Education Capacity and Strengthen Faculty Availability July 14, 2025
India’s Roads, India’s Pain: Healing Beyond the HospitalJuly 14, 2025
When Weathers Go Deadly: Role Of Climate Change In Stimulating The Proliferation Of Disease-carrying VectorsJuly 14, 2025
India’s Hidden Health Emergency: Climate Pressures on WellbeingJuly 14, 2025
The Silent Urgency: Why Geriatric Health Homes Can’t Wait AnymoreJuly 14, 2025
Rewiring the Brain: How Neuroscience Apps Are Changing Stroke RecoveryJuly 14, 2025
Healing Happens at Home: How Community Care Breaks the Cycle of Repeat Hospital TripsJuly 14, 2025
The Future Is Hands-On: How AR Is Quietly Reshaping Physical TherapyJuly 14, 2025
Flying Lifelines: Why Medical Drones are Changing Supply Chains in SilenceJuly 14, 2025
The Silent Hunger Are Well Fed Indian Teens Actually MalnourishedJuly 14, 2025
Richest 1% people have enough new wealth to end annual poverty 22 times overJuly 11, 2025
Fermenta Signs Strategic MoU with NIFTEM-T to Strengthen India’s Food Fortification LandscapeJuly 11, 2025
Sarvodaya Hospital, Greater Noida West, Launches Next-Gen Fully Active Robotic System for Joint ReplacementJuly 10, 2025
Children Dazzle the Stage at Faridabad Talent Hunt at Asian Institute of Medical SciencesJuly 10, 2025
From Macro to Mandate: How India's Affluent Investors are Positioning for Global ShiftsJuly 10, 2025
Actress-turned-Entrepreneur raises alarm over hidden pet health crisis in IndiaJuly 10, 2025